Clinical Trial Detail

NCT ID NCT00293475
Title Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors OHSU Knight Cancer Institute
Indications

central nervous system lymphoma

Therapies

Filgrastim

Pegfilgrastim

Leucovorin

Carboplatin + Methotrexate + Rituximab

Age Groups: adult

No variant requirements are available.